Insulin Resistance and Type 2 Diabetes: An Economic Perspective;Insulinresistenz und Typ-2-Diabetes: Eine Ökonomische Perspektive

Diabetes und Stoffwechsel

Volumn 12, Issue 3, 2003, Pages 135-144

  Bierwirth, Ralph Achim ^a,c   Funke, K ^a   Gruneberg M ^a   Leinhos, B ^a   Huptas, M ^a   Kron, P ^a   Lippmann Grob, B ^a   Munscher C ^b   Potthoff, F ^b  

^a Diabetologische Schwerpunktpraxis   (Germany)

^b MNC GmbH   (Germany)

^c Diabetologe ^*  (Germany)

Author keywords

Cost of illness; Direct medical costs; Insulin resistance; Macrovascular complications; Type 2 diabetes

Indexed keywords

CARDIOVASCULAR RISK; DRUG COST; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH CARE FACILITY; HOSPITAL CHARGE; HOSPITAL PATIENT; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; REVIEW; WORLD HEALTH ORGANIZATION;

EID: 0345255146     PISSN: 09420037     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21 (1998) 1414-1431
2. Liebl A, Neiß A, Spannheimer A, Reitberger U, Wagner T, Görtz A: Kosten des Typ-2-Diabetes in Deutschland. Dtsch Med Wochenschr 126 (2001) 585-589
3. MacLeod TM, Tooke J: Direct and Indirect Cost of Cardiovascular and Cerebrovascular Complications of Type 2 Diabetes. Pharmaco Economics 8 (1995) Suppl, 46-51
4. Brown JB, Nichols GA, Glauber HS, Bakst AW: Type 2 Diabetes: Incremental Medical Care Costs During the First 8 Years After Diagnosis. Diabetes Care 22 (1999) 1116-1124
5. Bagust A, Hopkinson PK, Maier W, Currie CJ: An economic model of the long-term health care burden of Type II diabetes. Diabetologia 44 (2001) 2140-1255
6. Henriksson F, Jönsson B: Diabetes: the cost of illness in Sweden. IHE Working Paper 1997:4
7. Selby JV, Ray GT, Zhang D: Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care 20 (1997) 1396-1402
8. Glauber H, Brown JB: Impact of cardiovascular disease on health care utilization in a defined diabetic population. J Clin Epidemiol 47 (1994) 1133-1142
9. Rubin RJ, Altman WM, Mendelson DN: Health Care expenditures for people with diabetes mellitus, 1992. J Clin Endocrinol Metabol 78 (1994) 809A-F
10. Brown JB, Nichols GA, Glauber HS, Bakst AW, Schaeffer M, Kelleher CC: Health care costs associated with escalation of drug treatment in type 2 diabetes mellitus. Am J Health-Syst Pharm 58 (2001) 151-157
11. Rathmann W, Haastert B, Roseman JM: Prescription Drug Use and Costs Among Diabetic Patients in Primary Health Care Practices in Germany. Diabetes Care 21 (1998) 389-397
12. Glauber HS, Brown JB: Use of Health Maintenance Organization Data Bases to Study Pharmacy Resource Usage in Diabetes Mellitus. Diabetes Care 15 (1992) 870-876
13. Evans JMM, MacDonald TM, Leese GP, Ruta DA, Morris AD: Impact of Type 1 and Type 2 Diabetes on Patterns and Costs of Drug Prescribing. Diabetes Care 23 (2000) 770-774
14. Haffner SM, Lehto S, Ronnemma T: Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
15. Pyörälä K, Laakso M, Uusitupa M: Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 3 (1987) 463-524
16. U.K. Prospective Diabetes Study (UKPDS) VIII: Study design, progress and performance. Diabetologia 34 (1991) 877-890
17. Margolis JR, Kannel WB, Feinleib M: Clinical features of unrecognized myocardial infarction: Silent and symptomatic. Eighteen year follow-up: The Framingham Study. Am J Cardiol 32 (1973) 1-7
18. Haffner SM, Stern MP, Hanley A, Williams K: Increased Cardiovascular Disease (CVD) Prior to the Onset of Type 2 Diabetes (DM) in the San Antonio Heart Study: The Role of Insulin Resistance (IR). Diabetes 50 (2001) Suppl 2, A649
19. Nichols GA, Glauber HS, Brown JB: Type 2 Diabetes: Incremental Medical Costs During the 8 Years Preceding Diagnosis. Diabetes Care 23 (2000) 1654-1659
20. De Fronzo RA, Ferranini E: Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesitiy, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease: Diabetes Care 14 (1991) 173-194
21. Facchini FS, Hua N, Abbasi F, Reaven GM: Insulin Resistance as a Predictor of Age-Related Diseases. J Clin Endocrinol & Metabolism 86, 8 (2001) 3574-3578
22. Smiley T, Oh P, Shane LG: The relationship of insulin resistance measured by reliable indexes to coronary artery disease risk factors and outcomes - a systematic review. Can J Cardiol 17 (2001) 797-805
23. Reaven GM: Banting Lexture 1988: The role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
24. D'Agostino RB, Ehrlich J, Stanford W, Schoentgen S, Savage PJ, Rewers M: Insulin Resistance Predicts Coronary Artery Calcification Independent of CVD Risk Factors or Diabetes Status. Circulation 106 (2000), P68
25. Haffner SM, D'Agostino R, Mykkänen L, Tracy R, Howard B, Rewers M, Selby J, Savage PJ, Saad MF: Insulin sensitivity in Subjects With Type 2 Diabetes: Relationship to cardiovascular risk factors: The Insulin Resistance Atherosclerosis Study. Diabetes Care 22 (1999) 562-568
26. Hsueh WA, Law R: Cardiovascular risk continuum: Implications of insulin resistance and diabetes. Am J Med 105 (1998) 4S-14S
27. Mykkänen L, Haffner SM, Ronnemma T: Low insulin sensitivity is associated with clustering of cardiovascular risk factors. Am J Epidemiol 146 (1997) 315-321
28. Hannoveraner Konsensusgruppe: Deutsche Empfehlungen zur gesundheitsökonomischen Evaluation. Revidierte Fassung des Hannoveraner Konsens. Dtsch Med Wochenschr 124 (1999) 1503-1506
29. Bierwirth RA, Kron P, Lippmann-Grob B, Funke K, Leinhos B, Grüneberg M, Huptas M, Weich KW, Münscher C, Potthoff F: Die TEMPO-Studie: Kostenanalyse in der diabetologischen Schwerpunktpraxis und Definition diabetesspezifischer Risikoprofile. Diab Stoffw 12 (2003) 83-84
30. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
31. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M: Prevalence of Insulin Resistance in Metabolic Disorders. The Bruneck Study. Diabetes 47 (1998) 1643-1649
32. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen MR, Groop L: Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome. Diabetes Care 24 (2001) 683-689
33. Biermann E, Rihl J, Standl E: Insulinresistenz und Typ-2-Diabetes: Die IRIS-Studie. Diab Stoffw 11 (2002) 150-158
34. Metzler W, Fischer S, Köhler C, Pistrosch F, Kindel B, Hanefeld M: Insulin resistance and metabolic parameters in type 2 diabetic patients. Eur J Intern Med 13 (2002) 108-114
35. Haffner SM, Williams K, Rozek MM, Stern MP: Homeostasis Model Assessment. Insulin Resistance In Relation To 8-Years Of Incidence Of Cardiovascular Diseases. Diabetologia 43 (2000) Suppl 1, A295
36. Henriksson F, Jönsson B: Diabetes: the cost of illness in Sweden. J Intern Medicine 244 (1998) 461-468
37. Warner DC, McCandless RR, De Nino LA: Costs of diabetes in Texas. Diabetes Care 19 (1992) 1416-1419
38. Ng YC, Jacobs P, Johnson JA: Productivity Losses Associated With Diabetes in the U.S. Diabetes Care 24 (2001) 257-261